Jump to Content
Jump to Main Navigation
Sign in
Sign up
HOME
BROWSE
ABOUT THE JOURNAL
Editorial Board
Journal Facts
Open Access Policy
Reprints/Permissions
Advertising
Contact Us
Privacy Policy
ISSUES
Current Issue
Previous Issues
Future Issues
Supplemental Issues
AHEAD OF PRINT
FOR AUTHORS
Submit a Manuscript
Author Instructions
Journal Policies
Transformative Journal Status
Author Fees
FOR SUBSCRIBERS
Members
Institutions
Cost
HELP
How to subscribe
Forgot Password
FAQ
COVID-19
ASTMH
Advanced Search
Help
ASTMH
Sign in
Sign up
HOME
BROWSE
ABOUT THE JOURNAL
Editorial Board
Journal Facts
Open Access Policy
Reprints/Permissions
Advertising
Contact Us
Privacy Policy
ISSUES
Current Issue
Previous Issues
Future Issues
Supplemental Issues
AHEAD OF PRINT
FOR AUTHORS
Submit a Manuscript
Author Instructions
Journal Policies
Transformative
Author Fees
FOR SUBSCRIBERS
Members
Institutions
Cost
HELP
How to subscribe
Forgot Password
FAQ
COVID-19
Search
Advanced Search
Help
The American Journal of Tropical Medicine and Hygiene
Print ISSN:
0002-9637
Online ISSN:
1476-1645
Previous Issue
Next Issue
Volume 106 (2022): Issue 5_Suppl (May 2022): Accelerating Innovation to Impact: Learning from Triple-drug Therapy (IDA) for Lymphatic Filariasis and from Other Innovations
Publication Date:
11 May 2022
Get eTOC Alerts
Get Ahead of Print Alerts
Cover
Cover
Contents
Contents
Acknowledgments
Acknowledgments
Articles
The Role of Innovation in Delivering the 2021–2030 Neglected Tropical Disease Road Map
Foreword: Towards Accelerating Tool Development for Global Health
Compressing the Timelines for Development and Delivery: Accelerating Access to Triple-Drug Therapy to Eliminate Lymphatic Filariasis
Lessons from Large-Scale Tolerability and Acceptability Studies of Triple Drug Mass Drug Administration Performed to Support Policy Change and Accelerate Elimination of Lymphatic Filariasis
Country Reports on Practical Aspects of Conducting Large-Scale Community Studies of the Tolerability of Mass Drug Administration with Ivermectin/Diethylcarbamazine/Albendazole for Lymphatic Filariasis
Accelerating the Uptake of WHO Recommendations for Mass Drug Administration Using Ivermectin, Diethylcarbamazine, and Albendazole
Introduction of Triple-Drug Therapy for Accelerating Lymphatic Filariasis Elimination in India: Lessons Learned
The Importance of Partnership in the Rollout of Triple-Drug Therapy to Eliminate Lymphatic Filariasis in the Pacific
Lessons Learned from the Japanese Encephalitis Vaccine Introduction in India That Supported the Introduction of Ivermectin–Diethylcarbamazine–Albendazole for Lymphatic Filariasis Elimination
Development and Introduction of the Filariasis Test Strip: A New Diagnostic Test for the Global Program to Eliminate Lymphatic Filariasis
Development and Introduction of Fexinidazole into the Global Human African Trypanosomiasis Program
Reflections on “Orchestrating for Impact”: Harmonizing across Stakeholders to Accelerate Global Health Gains
Save
Email this content
Share Link
Copy this link, or click below to email it to a friend
Email this content
or copy the link directly:
https://www.ajtmh.org/abstract/journals/tpmd/106/5_Suppl/tpmd.106.issue-5_Suppl.xml
The link was not copied. Your current browser may not support copying via this button.
Link copied successfully
Copy link
[3.231.217.107]
3.231.217.107
Sign in to annotate
Close
Edit
Character limit
500
/500
Delete
Cancel
Save
@!
Character limit
500
/500
Cancel
Save
View Expanded
View Table
View Full Size
